Darlene Noci

CDO Darlene Noci sells 20,000 shares at $122.81 via pre-arranged 10b5-1 plan; retains 58,117 shares plus 30,565 option-based holdings.

Darlene Noci, Chief Development Officer of Nuvalent, executed a scheduled sale of 20,000 shares for $2.5M on 2026-06-09 under a pre-arranged 10b5-1 trading plan adopted on 2024-11-18, reducing her direct holdings from 78.1K to 58.1K shares while retaining substantial derivative holdings across three tranches of stock options totaling 30,565 shares. The sale occurred near the company's 52-week high of $123.62, with the stock up 18.0% over the prior 30 days and 25.9% over 90 days. Her prior sales at this ticker (5 transactions in March 2025) were followed by 30-day declines ranging from -7.0% to -9.4% but positive 90-day returns of +5.8% to +8.9%, while her cross-ticker track record shows an average 90-day return of +4.9% following prior sells. The company remains unprofitable with a net income of $-109.3M against a market cap of $386.0M, which provides fundamental context for assessing the trade's significance. As a scheduled, non-discretionary transaction under a 10b5-1 plan, timing attribution is not applicable; the trade reflects a pre-planned execution rather than a discretionary decision point.

CDO Noci Darlene sold 34,000 shares (41.4% of holdings) for $2.4M at blended avg $71.87 on Mar 6–7.

Noci Darlene, Chief Development Officer, executed 5 separate sales totaling 34,000 shares for $2,443,578.02 ($2.4M) across two trading days, reducing her stake from 82.0K to 48.0K shares (a 41.4% reduction in holdings). The sales occurred at prices ranging from $70.65 to $72.60, with a blended average of $71.87, while the current price stands at $67.38—approximately 6.3% below the execution prices. Notably, the stock has declined 21.4% over the past 30 days and 27.5% over 90 days, and at her prior same-ticker sales at NUVL in March 2024, the stock fell further: the 90-day returns from those March 22, 2024 sells ranged from -0.4% to +1.5%, with only 1 of her 5 prior NUVL sales exhibiting negative 90-day returns (well-timed by the metric). The company reported a full-year net loss of $84.3M against a $210.9M market cap, signaling a materially unprofitable operation and constraining valuation cushion.